Rosiglitazone CV risk relative to metformin, sulfonylurea

July 2007
Reactions Weekly;7/21/2007, Issue 1161, p5
The article discusses research being done on the link between rosiglitazone, metformin, sulfonylurea and cardiovascular (CV) events. The study examined data obtained from the Ingenix Research Database between July 2000 and December 2004 for patients with type 2 diabetes receiving monotherapy with rosiglitazone, metformin or sulfonylurea, dual therapy with rosiglitazone plus sulfonylurea, rosiglitazone plus metformin or metformin plus sulfonylurea or insulin combined with rosiglitazone or other antidiabetic agents.


Related Articles

  • Fewer major cardiovascular events in type 2 diabetes with sitagliptin than with a sulphonylurea.  // British Journal of Hospital Medicine (17508460);Jan2012, Vol. 73 Issue 1, p9 

    The article offers an analysis of cardiovascular safety data from three previously published clinical studies, which shows that the incident rate of major cardiovascular events was less in type 2 diabetes patients taking sitagliptin (Januvia) compared to those taking sulphonylurea.

  • ADVERSE EFFECTS OF METFORMIN IN COMBINATION WITH GLIMEPIRIDE AND GLIBENCLAMIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Pravinkumar, V. Ingle; Gokul, S. Talele // Asian Journal of Pharmaceutical & Clinical Research;Jan-Mar2012 Supplement, p108 

    In type 2 diabetes mellitus, it is considered that the lowered insulin secretion and the lowered insulin sensitivity cause hyperglycaemia. Sulfonylureas have strong blood-glucose lowering effect by stimulating insulin secretion and have been widely used in the treatment of type 2 diabetes....

  • glibenclamide.  // Royal Society of Medicine: Medicines;2002, p268 

    This article presents information on the drug glibenclamide. It is a sulphonylurea and is used in diabetic treatment of Type II diabetes (non-insulin-dependent diabetes mellitus, maturity-onset diabetes). This drug works by augmenting what remains of production in the pancreas. It is orally...

  • Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes. Phung, Olivia J.; Scholle, Jennifer M.; Talwar, Mehak; Coleman, Craig I. // JAMA: Journal of the American Medical Association;4/14/2010, Vol. 303 Issue 14, p1410 

    The article offers information on a study which investigated the comparative efficacy, risk of weight gain and hypoglycemia linked with noninsulin antidiabetic drugs in patients with type 2 diabetes mellitus not controlled by metformin alone. A detailed description of study selection, data...

  • Higher Risk of Sulfonylurea-associated Hypoglycemic Symptoms in Women with Type 2 Diabetes Mellitus. Kajiwara, Ayami; Kita, Ayana; Saruwatari, Junji; Oniki, Kentaro; Morita, Kazunori; Yamamura, Masato; Murase, Motoji; Koda, Haruo; Hirota, Seisuke; Ishizuka, Tadao; Nakagawa, Kazuko // Clinical Drug Investigation;Sep2015, Vol. 35 Issue 9, p593 

    Background: Although some evidence suggests that women may be at greater risk for hypoglycemia, no conclusion has been reached, and female sex has not been taken into account in antidiabetic drug-induced hypoglycemia. This study aimed to determine whether females are at a higher risk of...

  • Perspective: General practice. Gadsby, Roger // Diabetes & Primary Care;2013, Vol. 15 Issue 6, p290 

    The author comments on a study which reveals the risks for cardiovascular disease (CVD) associated with the use of the glucose-lowering agent sulphonylurea.

  • Perspective: Prescribing advisors. Newland-Jones, Philip // Diabetes & Primary Care;2013, Vol. 15 Issue 6, p290 

    The author comments on the increased cardiovascular disease risk associated with the use of the glucose-lowering agent sulphonylurea. He believes that formulary developers and prescribing advisors should be aware of the risks of hypoglycaemia prior to prescribing sulphonylureas. He suggests...

  • Case Study--Managing newly diagnosed type-2 diabetes. Bostock-Cox, Beverley // Independent Nurse;6/4/2010, p1 

    The article presents a case study of a 58-year old man, Charlie, who underwent an axillary abscess and was diagnosed as a possible candidate for diabetes. Several changes in his lifestyle and dietary habits for reducing risks of cardiovascular diseases and a continuous monitoring routine were...

  • Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data.  // Cardiovascular Diabetology;2012, Vol. 11 Issue 1, p6 

    The article presents a research which examines the efficacy of cardiovascular (CV) safety of the selective dipeptidyl peptidase-4 (DPP-4) inhibitor saxagliptin for the treatment of type 2 diabetes mellitus (T2DM). It is reported that, the researchers carried out a retrospective meta-analysis to...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics